1. Парфенов В..А., Рыжак А.А. Неврологические аспекты оптимизации антигипертензивной терапиии. Невролог. журн. 2003; 2: 26–9.
2. 2. Парфенов В.А., Старчина Ю.А., Яхно Н.Н. Эпросартан (Тевтен) в профилактике повторного инсульта и когнитивных нарушений. Там же. 2007; 1: 46–51.
3. Шевченко О.П., Праскурничий Е.А., Яхно Н.Н., Парфенов В.А. Артериальная гипертония и церебральный инсульт. М., 2001; 192.
4. Фейгин В., Виберс Д., Браун Р. Инсульт: Клиническое руководство. М.: Бином; СПб.: Диалект, 2005; 608.
5. Amarenco P, Bogousslavsky J, Amarenco P et al. High- dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
6. Barnett H, Taylor D, Eliasziw M et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998; 339: 1415–25.
7. Chalmers J, MacMahon S, Anderson C et al. Clinician’s manual on blood pressure and stroke prevention. 2-d ed. London, 2000; 129.
8. Farmer JA, Torre-Amione G. The renin-angiotensin system as a risk factor for coronary artery disease. Curr Atheroscler Rep 2001; 3: 117–24.
9. Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med J 1995; 108: 710–7.
10. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient schaemic attack. Lancet 2001; 358: 1033–41.
11. Rothwell PM, Howard SC, Spence JD, for the Carotide Endarterectomy Trialist`s Collaboration. Relationship between Blood Pressure and Stroke Risk in Patients With Symptomatic Carotid Occlusive Disease. Stroke 2003; 34: 2583–92.
12. Sacco RL, Adams R, Albers G et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577–617.
13. Schrader J, Luders S, Kulschewski A et al. Mortality and morbidity after stroke, Eprosartan compared with Nitrendipine for secondary prevention. Principal results of a prospective randomised controlled study (MOSES). Stroke 2005; 36: 1218–26.